Zubeda Syeda, Kaipa Prabhakar Rao, Shaik Noor Ahmad, Mohiuddin Mohammed Khaliq, Vaidya Sireesha, Pavani Boddana, Srinivasulu Mukta, Latha Manolla Madhavi, Hasan Qurratulain
Department of Genetics and Molecular Medicine, Vasavi Medical and Research Centre, Andhra Pradesh, India.
Asian Pac J Cancer Prev. 2013;14(4):2231-5. doi: 10.7314/apjcp.2013.14.4.2231.
Categorizing breast tumors based on the ER, PR and HER/Neu 2 receptor status is necessary in order to predict outcome and assist in management of breast cancer. Herfe we assessed this question in South Indian patients.
A total of 619 formalin fixed paraffin embedded breast tumor tissues were collected from pathology archives after receipt of ethical clearance. With the help of primary and secondary conjugated antibodies, expression status of ER, PR and HER2/neu was determined. All the experimental data were assessed for correlations with histopathological features of tumors and clinical presentation of the subjects.
In the present study, the ages ranged from 20-87 years with a mean of 50.0±12.q years, and majority of the tumors (84%) were of infiltrating duct cell carcinoma type. Assessment of ER, PR and Her-2/neu expression showed that 46% were triple negative. Interestingly, an inverse relation between ER, PR and HER-2/neu was apparent in 41.2% (p<0.0001) of the tumors, of which 24.5% (p<0.0001) were ER and PR co-negative but HER-2 positive.
ER and PR positive tumors are less common (i.e<30%) compared to HER-2/neu positive tumors (i.e>50%) in Indian breast cancer patients, underlining the need for effective diagnostic screening and specific therapeutic managements in order to improve the survival rate of patients in low resource countries such as India.
根据雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER/Neu 2)受体状态对乳腺肿瘤进行分类,对于预测乳腺癌的预后及辅助治疗十分必要。在此,我们对印度南部患者的这一问题进行了评估。
在获得伦理批准后,从病理档案中收集了619份福尔马林固定石蜡包埋的乳腺肿瘤组织。借助一抗和二抗共轭抗体,确定ER、PR和HER2/neu的表达状态。所有实验数据均评估与肿瘤组织病理学特征及受试者临床表现的相关性。
在本研究中,患者年龄范围为20 - 87岁,平均年龄为50.0±12.q岁,大多数肿瘤(84%)为浸润性导管细胞癌类型。ER、PR和Her-2/neu表达评估显示,46%为三阴性。有趣的是,41.2%(p<0.0001)的肿瘤中ER、PR和HER-2/neu之间存在明显的负相关,其中24.5%(p<0.0001)为ER和PR均阴性但HER-2阳性。
在印度乳腺癌患者中,ER和PR阳性肿瘤(即<30%)比HER-2/neu阳性肿瘤(即>50%)更少见,这凸显了在印度等资源匮乏国家需要有效的诊断筛查和特定的治疗管理措施,以提高患者的生存率。